← back to search

Maria Fleseriu

Oregon Medical Research Center · US
Area of research
Endocrinology, Diabetes and Metabolism · Surgery
Research interest
Research interests include Pituitary Gland Disorders and Treatments, Growth Hormone and Insulin-like Growth Factors, Adrenal Hormones and Disorders, and Adrenal and Paraganglionic Tumors.
h-index
60
citations
14,130
works
528
NIH funding
primary concept
Acromegaly
email

Recent publications

Osilodrostat-associated Adrenal Gland Shrinkage: A Case Series of Patients With ACTH-dependent Cushing's Syndrome.
2026cited by 4position: contributordoi
Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results.
2026cited by 2position: contributordoi
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment.
2026cited by 1position: contributordoi
Impact of sex on mortality in patients with pituitary adenomas.
2026cited by 0position: contributordoi
Acromegaly Complications: An Update.
2026cited by 0position: contributordoi
A Novel Evaluation of 24-hour Energy Metabolism in Cushing's Syndrome: The Metabolic Cost of Hypercortisolism.
2026cited by 0position: contributordoi
Approach to the Patient with Cushing's Syndrome: Use of Anticoagulation Therapy.
2026cited by 0position: contributordoi
Consensus on acromegaly complications: an update.
2026cited by 0position: contributordoi
Consensus on acromegaly complications: an update
Pituitary 2026cited by 0position: middledoi
Consensus on acromegaly therapeutic outcomes: an update
Nature Reviews Endocrinology 2025cited by 36position: middledoi
Consensus on acromegaly therapeutic outcomes: an update.
2025cited by 23position: contributordoi
Pituitary incidentaloma: a Pituitary Society international consensus guideline statement.
2025cited by 18position: contributordoi
Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies
Pituitary 2025cited by 16position: firstdoi
Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study
Journal of the Endocrine Society 2025cited by 12position: firstdoi
Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement.
2025cited by 12position: contributordoi
Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study.
2025cited by 10position: contributordoi
Identifying research priorities for pituitary adenoma surgery: an international Delphi consensus statement
Pituitary 2025cited by 8position: middledoi
Mortality in Cushing's syndrome: declining over 2 decades but remaining higher than the general population.
2025cited by 7position: contributordoi
Prolactin-secreting adenomas: pathogenesis, diagnosis, and management.
2025cited by 6position: contributordoi
Cycle characterisation and clinical complications in patients with cyclic Cushing's syndrome: insights from an international retrospective cohort study
The Lancet Diabetes & Endocrinology 2025cited by 5position: middledoi
Osilodrostat Treatment for Adrenal and Ectopic Cushing Syndrome: Integration of Clinical Studies With Case Presentations.
2025cited by 5position: contributordoi
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.
2025cited by 4position: contributordoi
Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis.
2025cited by 4position: contributordoi
PANOMEN-3 grading score is reliable in predicting pituitary adenoma behavior and prognosis: a single center cohort study.
2025cited by 3position: contributordoi
Weight gain reversibility and BMI following treatment for Cushing's syndrome: long-term outcomes and potential predictors.
2025cited by 2position: contributordoi
Leukocytosis in Cushing's syndrome persists post-surgical remission and could predict a lower remission prognosis in patients with Cushing's disease.
2025cited by 2position: contributordoi
Hypercoagulability in Cushing's syndrome: past, present, future.
2025cited by 1position: contributordoi
Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD).
2025cited by 1position: contributordoi
Predictors of cancer in patients with endogenous Cushing's syndrome.
2025cited by 1position: contributordoi
Impact of remission status in endogenous Cushing's syndrome on cancer incidence.
2025cited by 1position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 89 papers (2019–2026)Шломо Мелмед · Cedars-Sinai Medical Center14 papers (2016–2025)Amit Akirov · Tel Aviv University10 papers (2022–2025) · 8 papers (2021–2025)Rosario Pivonello · Elsevier, Inc.8 papers (2021–2025)Mônica R. Gadelha · University of Edinburgh7 papers (2014–2025)Beverly M. K. Biller · University of New Mexico7 papers (2012–2025)Stephan Petersenn · ERT (Germany)7 papers (2019–2024)Tzipora Shochat · Tel Aviv University7 papers (2024–2025)Ilan Shimon · Hebrew University Hadassah Medical School7 papers (2024–2025)Monica R. Gadelha · Takeda (Japan)7 papers (2019–2024)Shiri Kushnir · Rabin Medical Center7 papers (2024–2025)Yaron Rudman · Tel Aviv University7 papers (2024–2025)J. Newell-Price · Oregon Medical Research Center6 papers (2019–2025)B. M. K. Biller · Oregon Medical Research Center6 papers (2021–2026)Yona Greenman · Hospital Universitari Germans Trias i Pujol6 papers (2021–2025)Alberto M Pedroncelli · Novartis (Switzerland)6 papers (2014–2025)Hidenori Fukuoka · Niigata University5 papers (2019–2026)Hiba Masri-Iraqi · Tel Aviv University5 papers (2024–2025)Alberto M. Pereira · University Vascular Associates5 papers (2023–2026)